Mainz Biomed Partners With Liquid Biosciences To Harness The Power Of Artificial Intelligence To Develop Colorectal Screening Test
Portfolio Pulse from Benzinga Newsdesk
Mainz Biomed has partnered with Liquid Biosciences to extend the use of EMERGE in its product development pipeline. This includes analysis of its eAArly DETECT study and the forthcoming U.S. pivotal FDA PMA trial (ReconAAsense). If successful, this will allow Mainz Biomed to advance its current test's capabilities and commercialize a next-generation colorectal cancer screening tool. The eAArly DETECT clinical trial is enrolling 265 subjects across 22 sites and is expected to report results in Q4 2023.

November 09, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mainz Biomed's partnership with Liquid Biosciences to develop a next-generation colorectal cancer screening tool could potentially enhance its product offerings and market position if successful.
The partnership with Liquid Biosciences allows Mainz Biomed to leverage AI in its product development, potentially leading to the commercialization of a next-generation colorectal cancer screening tool. This could enhance its product portfolio and strengthen its market position, positively impacting its stock in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100